Home / Transcripts / Teva Pharmaceutical Industries Limited (TEVA) · July 29, 2026

Teva Pharmaceutical Industries Limited (TEVA) Earnings Call Transcript

July 29, 2026

New York Stock Exchange US Health Care Pharmaceuticals earnings 69 min

Earnings Call Speaker Segments

Chris Stevo executive
#1

Thanks, Elliot. Hello and good afternoon to all of you. We appreciate you being with us for the call covering our second quarter. As you're aware, our materials went up on the website earlier today, so kindly take a look at those. And prior to handing things over to Richard Francis, our CEO, I want to remind everybody that forward-looking statements will be part of this call. The company wants investors to understand that any forward-looking statement carries risks and uncertainties and should not be viewed as a promise of future performance. Because of a range of factors, actual results could differ materially from what those forward-looking statements express or imply; those factors are laid out in our earnings press release along with our most recent forms 10-Q and 10-K filed with the SEC. Everything we say reflects only today, and we take on no duty to update these statements at a later point. So, Richard Francis.

Richard Francis executive
#2

Appreciate it, Chris, and greetings to everyone this morning and this afternoon. We're glad you could be on today's call. Joining me for this session are Dr. Eric Hughes, who leads Global R&D and serves as Chief Medical Officer, along with Eli Kalif, our Chief Financial Officer. Now, let's turn to the question of how we kick off the pivot to growth side. The strategy we rolled out in 2023 rests on those same 4 pillars. We'll recap our performance against those 4 pillars for quarter 2. But first, a quick look at how our growth engines are delivering — AUSTEDO, AJOVY and UZEDY all posted strong Q2 results, and we're lifting our full year revenue guidance for these products; it bears repeating that the innovative portfolio is reshaping our financial profile, bringing stronger revenue growth, margins and free cash flow. Turning to pillar two, stepping up innovation in our pipeline, this year will bring 8 major milestones, and that now takes in ecopipane, which offers us the potential for 5 submissions across the next 5 years; as for building the generics powerhouse, biosimilars are turning into a growth platform inside generics. At present we have 15 products on the market and 14 in our pipeline, and we see further opportunities via additional partnerships. On the last pillar, focusing the business, I believe we've achieved great progress with capital allocation. One of the agencies, Fitch, has moved us up to investment grade, and we expect the remaining 2 to follow in the not-too-distant future. We also put capital toward acquiring Amylyx. That deal closed in June, and we anticipate a launch next year should the FDA approve it. And lastly, converting the ADS into ordinary shares plus the ability to list on the New York Stock Exchange ought to make investing in Teva accessible to a greater number of investors. Now, on to the financials. I'm genuinely proud of this slide, and you might wonder why, so let me take you through the reasons. We now have stable revenues even with nearly 8% of headwinds from generic REVLIMID loss year-over-year; we're also expanding our profit margin, 80 basis points, with gross margins improving year-over-year, powered by strong innovative growth despite that loss of genetic REVLIMID. We've in fact grown our EBITDA, clearly excluding the Amylyx acquisition. And our free cash flow has risen 31% thanks to our disciplined capital allocation; now, if I move to the next slide, I'll provide a bit more detail. As you can see, the innovative portfolio delivered a strong quarter, up 43% year-on-year. AUSTEDO, up 40%; UZEDY, up 43% and AJOVY, up 56%. Generics is down 15%, and that's mostly because of lower generic contribution versus 2025. But if I go into a bit more detail now, beginning with AUSTEDO, a core growth driver here. We had another impressive quarter. Stateside, we brought in $676 million, which is a 33% increase compared to the same period last year, while worldwide sales climbed 40%. Demand stayed robust, with TRx rising 14% and milligram volume expanding 21%, driven by people starting treatment and staying on it. More than 60% of patients beginning therapy are now on AUSTEDO XR, which boosts ease of use, compliance, and lasting benefits. Given how well this quarter went, we're raising our guidance by $50 million at the midpoint. That brings it to between $2.45 billion and $2.6 billion. Keep in mind the midpoint sits at $2.5 billion — the very goal we set for ourselves back in 2027 — so there's a real possibility we surpass it ahead of schedule. More crucially, though, we're seeing ongoing momentum and a large group of untreated patients who could still gain from AUSTEDO, which is why we feel confident about eventually hitting more than $3 billion in peak sales. Switching to UZEDY now. UZEDY keeps expanding with solid momentum. Among atypical LAIs, it's the long-acting injectable for schizophrenia that's growing the quickest. Sales rose 43% to $77 million in Q2 thanks to robust demand, and our TRx jumped 63% versus the prior year. The commercial team has done outstanding work, evidenced by UZEDY almost doubling the risperidone long-acting portion and moving from 5% to close to 10%; UZEDY is now grabbing almost 80% of the risperidone LAI segment. Given these results, we're lifting our guidance by $15 million at the midpoint, making the new range $270 million to $290 million. This ongoing excellent performance gives us strong belief in the forthcoming olanzapine launch, which I'll turn to now. Olanzapine stands as a major next avenue for growth, with FDA action and a U.S. rollout expected in Q4 of this year. The unmet need here is considerable. Olanzapine accounts for about 20% of all U.S. prescriptions, yet olanzapine LAI makes up under 1% of the LAI category. We understand this space well; we can truly capitalize on synergies with UZEDY, plus our deep familiarity with the schizophrenia market — be it doctors, patients, nurse practitioners, or certain long-term care settings. Our path forward is obvious: execute a best-in-class launch that broadens treatment choices and cements our leadership in LAIs. Combined, olanzapine and UZEDY provide a strong route to anticipated peak sales between $1.5 billion and $2 billion. Turning to AJOVY now. AJOVY shows we can perform in tough, innovative markets no matter where they are. We keep surpassing injectable market growth, and we're number one in numerous markets even though we arrived later. Q2 global sales hit $244 million, a 56% rise year-over-year. U.S. sales were up 83%, fueled by better contracting, favorable gross to net, and share gains. Outside the U.S., momentum stayed solid, backed by volume increases and top brand shares throughout Europe and international territories. Because of this robust quarter, we're boosting our outlook by $90 million at the midpoint. So the range now sits at $850 million to $870 million. Then, when we look past 2026, there's a clear path toward $1 billion in peak sales for AJOVY. Turning to the newest addition to our innovative family, this is a first-in-class opportunity offering compelling efficacy along with favorable tolerability in Tourette syndrome, a serious pediatric neurological disorder where treatment options are limited. We've already submitted our filing to the FDA, with a potential launch in the first half of 2027. The unmet medical need here is obvious. 100,000 pediatric patients are living with Tourette syndrome, just 50,000 receive treatment, and merely 20% to 30% stay on therapy beyond 1 year. That demonstrates a genuine need for a product with compelling efficacy and favorable tolerability. We're well positioned to deliver on this, drawing on our CNS capabilities and the experience gained with AUSTEDO, AJOVY, and soon-to-be long-acting olanzapine. This brings us to a slide I've never had the chance to show before, in my rather long career, actually. I apologize for the small font, but we needed to fit everything onto 1 slide. What it highlights is simply the innovative pipeline we possess and our potential to launch 1 asset per year over the next 5 years, transforming Teva into a leading biopharma company.

Richard Francis executive
#3

Looking ahead, the launches coming soon follow a clear order: olanzapine arrives in '26, then in '27, with DARI coming after that, and then Q2 '28 through '30. Naturally, every one of these depends on getting regulatory approvals. But when we look out to '35, additional upside appears from the extra indications we've already announced, both for dubicictid and the added indication for anti-I15, plus our other efforts. We're also chasing additional business opportunities and development opportunities too. Now let me turn to our pipeline slide. I'll keep my comments brief here and let Eric walk through it in more detail, though a few points deserve a mention. To start, like I mentioned during my opening comments, this pipeline is right around the corner and packed with catalysts; with agile, we received the Vitiligo results, and CDEC data is expected in the latter half of the year. We've got those upcoming launches involving olanzapine along with filed. DARI is progressing well. We've shared news of 2 additional indications for Ducato. When you put all these assets together, they represent over $10 billion in peak sales, although I know we've made that claim previously, and that number predates both our recent addition to this slide and the 2 new indications, so I must keep in mind to revise it. So, what's the takeaway from all this for Teva? This is going to reshape the way our growth looks in a fundamental way. We are seeing a real acceleration, as revenue has risen from $4.9 billion in 2022 and is now expected to reach between $16.5 billion and $16.8 billion for this year. On top of that, our portfolio continues to move toward innovation that carries greater value, and innovative revenue is expected to represent 22% of total revenue in 2026, compared with 9%, and by 2030 you can see where that path takes us. Now on to margins, where we are creating stronger results, with gross margins expected to grow from 54% to more than 60% by 2030 plus. Again, it is our inhibitive portfolio that is driving this. Let me now turn to our generics business. Compared with Q2 2025, our generics business has fallen 15%. Even so, I don't think that tells the full story. When you set aside generic REVLIMID, things in our generics segment were basically flat. Global Generics slipped 2%, the U.S. gained 1%, and the drop outside the U.S. was driven largely by a lighter slate of launches this year along with the cost and cold season. Although 2026 looks like it will be a bit softer, we still view this as a steady generics operation that can produce 1% to 2% growth each year over the long run, backed by a consistent cadence of new products coming to market. My enthusiasm for where our generics business is headed has not faded at all. One big factor behind my confidence is the growth rate beginning to show up in our biosimilar portfolio and pipeline. Let me turn to that topic now. Biosimilars, then, are reshaping the generic side of our business. Prior to the pivot to growth, the count stood at 3. As of now, 15 are on the market. Over the coming years, we anticipate that figure will double. It isn't merely portfolio scale that matters — execution does too. In America, 2 out of the 5 products we sell rank number one, and a third shares the lead, which I believe will soon be outright first. Now turning to America — apologies, to the EU — where 3 biosimilars were launched only recently, and early signals appear fairly positive. We keep pursuing partnerships so this portfolio can grow, and given how well we execute, my sense is that we are turning into the preferred collaborator; with the pace we currently have, surpassing our $800 million by 2027 is within reach. Before passing things to Eric, to wrap up, we remain on course to achieve our financial growth objectives: mid-single revenue growth, a non-GAAP operating income target of 30%, net debt to EBITDA under 2%, and cash conversion earnings of 80%. So, I'll now pass it to Eric.

Eric Hughes executive
#4

Thanks, Richard. Now let's turn to slide one. Richard already touched on this briefly, I realize, but I wanted to begin by noting that things have gotten quite complex—though complex in an excellent way. We're looking at five possible submissions across five years. Let me just point out a handful of key items on this slide. We've added ecopitane, submitted back in June for Tourette syndrome. We've also added two fresh indications for Duvaqetob: hydrogenitis superteva and fibrosenatic Crohn's disease. Those are two quite significant indications, and I'll cover them in more depth a bit later. Still, it's wonderful to see this pipeline, and we're working on it daily. Let me begin with olanzapine LAI. The action date in Q4 of this year remains on schedule; our EU MAA was accepted earlier in the year. We also just presented several abstracts at the psych Elevate Conference and the Page conference. So everything is moving forward right now with olanzapine LAI, and we anticipate approval by year's end. Turning to ecopitane: one thing that excites me right off the bat is that this mechanism is a completely novel, first-in-class D1 antagonist. Even more significant, though, is that this marks the first dedicated launch of a Tourette syndrome treatment, so I believe disease awareness plus delivering a new option for a substantial unmet medical need will be a crucial part of this launch. I take pride in the fact that we have two well-controlled studies: the Phase II demonstrated a reduction in tic syndrome that was not just statistically significant but clinically meaningful, and in Phase III we also demonstrated a drop in relapse rate that was both statistically and clinically significant, at a 50% reduction. All of these are encouraging signals; above all, though, this is a therapy that's well tolerated and durable. Among patients in the long-term follow-up, 66% stayed on treatment with sustained tic reduction, and we anticipate that approval next year—something to look forward to. Now on to our DARI program, the dual action rescue inhaler for asthma. Enrollment is complete at over 2,700 patients, spanning pediatric, adolescent, and adult populations. We remain right on schedule for that final event. This study is event-driven. Our projection is the end of this year, and we'll be in a position to present those data in the early half of 2027. This is truly a strong program for asthma patients. It addresses an unmet medical need, meeting the need and the treatment called for in the guidelines. We'll be offering an excellent therapy: a dual action retail with a dry powder inhaler that's simple to use, and potentially a label that covers pediatrics. Now let's move to Duvaqito—very exciting this year. We shared our induction data in Nolans, with two manuscripts appearing in parallel—one on ulcerative colitis, the other on Crohn's disease. Seeing the team's efforts acknowledged by a journal of such high impact feels wonderful, and credit goes to them for outstanding work. So congratulations to the team. Beyond that, on Duviqita, the Phase III program we're running alongside our partner Sanofi, everything remains fully on schedule. That covers our Sunscape and Starscape programs in ulcerative colitis and Crohn's disease. Today, though, we're extremely proud to share that two additional indications are joining our research: hydrogeni superativa, which opens up that non-T2-based indication group, and fibrosin Crohn's disease, which opens the fibrotic bucket of indications while also broadening and reinforcing our focus and labeling for IBD going forward. This announcement, made together with our partner Sanofi, is truly exciting. I'll say more shortly about why these two indications matter. Starting with hydrogen super tivo—an area I've worked in previously. It represents a significant unmet medical need. It arises from painful inflammatory abstasies that affect skin folds across the body. These patients endure their condition quietly, and the many facets of the disease can be disfiguring and genuinely disrupt daily life. It isn't rare—roughly 1% of adults have it. Treatments have received approval, yet much ground remains to be covered regarding the efficacy we can deliver. Anti-1 therapy strikes me as ideally matched here. This disease is complex, drawing on multiple pathways that involve Th1 and Th17 cells, and a notable fibrotic element is present, so the pleiotropic effects of TL1A therapy could fit particularly well. Worth noting too: 15% of individuals with IBD also have hydro genius supertiba. That gives us substantial scientific rationale, and it's a meaningful market where we can expand. Additionally, we discussed fibrosynotic Crohn's disease. This represents a highly significant facet for people living with Crohn's. We've already shared Phase II results showing strong efficacy from our Phase II trial with duvacitub. Now, however, we're examining even more severe Crohn's cases. Half of those with Crohn's disease carry this fibrostynotic component, and here fibrosis, inflammation and edema bring about near-complete obstruction of the gut, which drives more hospitalizations, more surgeries, and higher health care cost. It genuinely fuels some of the most devastating elements of Crohn's disease. So we're delighted to push the science forward. Nothing has won approval for this indication as of now. I believe this demonstrates our confidence in Crohn's disease and our desire to double down and make that label as patient-friendly as we possibly can. I'm really thrilled that we're looking into this particular condition with duvaqito. Now, let's turn to something else: we presented impressive results last month from our proof-of-concept trial involving vitiligo patients and our anti IL-15 program. I typically begin by emphasizing that, above all, it was encouraging to observe how patients' views of their illness shifted. Specifically, 75% of those in the study noted betterment in the vitiligo affecting their faces. In this slide, I'm displaying 2 individuals who granted specific permission to reveal what they experienced during the trial. Keep in mind that these 2 people received only 2 doses of our anti IL-15 antibody, and across a 24-week span, you can observe a significant transformation in both the female patient on the left side and the male patient on the right side — nearly complete repigmentation of the cheeks for the woman, which filled in quite well throughout those 24 weeks. As for the individual on the right, there were striking shifts from widespread deep loss of pigment in darker skin; these outcomes altered how patients perceived things and were achieved quite easily with merely 2 injections. Yet despite my satisfaction regarding the shift in patient perception, we likewise achieved the key regulatory targets. The figures we reported for the 50, the F 75, and the T body are highly favorable compared to other systemic treatments available for this condition.

Eric Hughes executive
#5

And this truly made clear that we moved straight into our Phase IIb/III trial, which is going to be run and kicked off during this year, so our pace is quick. We can't wait to see what the data shows, and we're proceeding as fast as we can. And lastly, I want to touch on what lies ahead. So a readout is coming in the back half of this year, along with our second Celiac proof-of-concept trial; that trial matters a lot since it's in fact examining biopsy findings following a gluten challenge. So keep in mind, the fundamental pathology of Celiac disease is that when an immune reaction to gluten occurs, the normal bile in the gut gets destroyed, and where you have that lovely high surface area of villus that takes up nutrients in the gut, when a patient with CIC disease consumes gluten, there is nearly total destruction of that normal villus on — as histology shows; and we're hoping to observe in the scrutiny challenge through the biopsies that we do, in fact, shield the villi from such destruction when the anti-IL-1 treatment is used. So we're eagerly awaiting the readout. That's going to arrive in the back half of this year, but I believe this could be a major step forward for patients with CAC potentially, on the basis of those data. So on my last slide, I simply want to go through the fact that throughout 2026 we are marching through our milestones. We presented the maintenance data first this year for duvaqito. We completed the filing for Ecopytan, our new player on the field. And then, for our anti-IL-5 program, we also recently presented the vitiligo data. The Celiac data will come in the back half of this year. DARI remains on track for that final event, that final exacerbation, before this year ends, and we'll have those data to discuss in the early portion of 2027. Emera Solman remains on track for the futility analysis as the year closes. We're anticipating approval of olanzapine LAI as this year ends, and by the end of this year we'll also have some anti-PD-1 IL-2 human data. So it's very exciting. We continue executing, and we look forward to all of these events this year. And with that, I'll hand things over to my colleague, Eli Kalif.

Eliyahu Kalif executive
#6

Thank you, Eric, and greetings to all, whether it's morning or afternoon where you are. I'd like to kick off my review of how we performed in Q2 '26 with these main points: To begin, we turned in a robust second quarter, once more powered by the ongoing momentum of our portfolio of innovative products. Next, as revenues from innovative offerings make up a growing share, combined with the transformation programs we've put in place, we're still on course to hit our goal of a 30% operating margin by 2027. And finally, our strategy of allocating capital with discipline, along with how we execute, is getting more and more recognition from top credit rating agencies, such as the upgrade to investment grade we recently received from Fitch; let's now turn to Slide 34. Before getting into our Q2 results, allow me to quickly go over the MLX Basins acquisition, which we closed in June. As Richard pointed out before, it further bolsters our standing in CNS, a space where our commercial and development strengths are already solid. When it comes to accounting, as we talked about last quarter, this deal was accounted for as an asset acquisition. Consequently, we booked $724 million as IP R&D expenses in the second quarter; that figure covered the upfront cash consideration, net liabilities we took on, and the costs tied to the transaction. The upfront consideration moves through cash flow from investment activities, so it has no effect on free cash flow. As I walk through our Q2 performance, I'll be referencing how MLX affected our financials so you can get a clearer picture of how we did on an underlying basis; let's begin with our Q2 GAAP results on Slide 35. Q2 revenues came to roughly $4.1 billion, a decline of 1% in U.S. dollars, or 3% in local currency, versus Q2 2025. That drop stemmed mostly from weaker generics, primarily generics REVLIMID, and was mostly offset by sustained robust expansion of our key innovative products, AUSTEDO, AJOVY and UZEDY. GAAP net loss came in at $576 million, with loss per share of $0.49. Let's shift now to how we did on a non-GAAP basis. Our non-GAAP gross margin for Q2 '26 reached 55.4%, up 80 basis points, which mirrors strong growth in our innovative portfolio. Non-GAAP operating margin stood at 9%, and that includes $726 million in expenses related to MLX. If you take out MLX, our non-GAAP margin would have come to 26.6%, a touch under Q2 of last year, mostly because of increased planned investments in sales and marketing during the first half of this year aimed at supporting our innovative growth. All told, we closed out the quarter with non-GAAP EPS of $0.02. MLX's effect on EPS amounted to $0.61, and absent that, our non-GAAP EPS would have reached $0.63. Free cash flow for Q2 was robust, hitting $622 million, which is 31% higher than a year ago. To give you a bit more detail, our Q2 '25 results had included $318 million in revenue and $223 million in EBITDA contribution from our generic REVLIMID. Our financial results for this quarter showed strong underlying performance once you strip out the effect of generics REVLIMID. On to the next slide. As a reminder, 2 structural elements are what drive our operating margin expansion to 30%. To start, there's a shift in our portfolio toward innovative products that deliver greater growth and better margins. Then there's the transformation program we've put in place. Combined, that adds up to roughly 400 basis points of gains since this program was unveiled in May of last year, even with generic REVLIMID weighing on us. This sits at the heart of how we're reshaping our finances — evolving from a business that was traditionally generics-led into one that's… well, a bar from a company; we keep moving forward toward hitting those targets, as our 2026 guidance shows. Let's turn to Slide 37. If we examine the opening six months of 2026, the base business keeps proving out how well our strategy and execution are working. What you're seeing is that first-half revenue results capture robust expansion across our innovative portfolio and biosimilars, which more than offsets over $600 million in revenue lost to generics REVLIMID. Our non-GAAP operating margin during that first half likewise shows continuing gains in our gross margin profile. As I mentioned three months ago, we anticipated that operating expenses would be heavier in the first six months of this year compared with the latter six months, largely because of how planned investments are timed to back our expanding innovative portfolio and the launches coming up; we look for OpEx to settle back as operating leverage kicks in and transformation program savings have greater effect during the second half. Let's move to Slide 38. Our balance sheet keeps getting stronger, and that's a crucial enabler of the Pivot to Growth strategy, fueling EPS and free cash flow. Across the past several years, we've made substantial enhancements to our leverage profile. At the close of — our net debt stood at $12.9 billion, with a net debt-to-EBITDA ratio of 2.8x. If you set aside MLX, our net debt-to-EBITDA would have come in at 2.3x, which keeps us well on track to reach our 2x target by 2027. As we keep paying down what we owe, that should translate into meaningfully reduced finance expenses by 2030. Meanwhile, we've kept reshaping how we manage working capital, generating considerable improvement as a share of revenue, which brings down our cash conversion cycle. Those efforts, taken together with our rapidly expanding innovative portfolio and transformation programs, should fuel long-term growth in earnings and free cash flow. On the following slide, you can see that our execution is gaining more and more recognition from the top credit hedging agencies. Back in May, Fitch raised Teva to an investment-grade rating, which means Teva has returned to IG for the first time since 2017. That marked our third upgrade from Fitch in under 2 years, which speaks to Teva's transformation journey. Roughly 2 quarters back, S&P and Moody's had also raised our rating and outlook, respectively. These upgrades serve as further proof of our disciplined execution and stronger financial profile. With our ongoing transition into an innovative biopharma company, we're well positioned to secure further rating upgrades. Now, let's look at our 2026 outlook on Slide 4. Given the strength we saw in the first half and what we can see for the second, we're lifting the midpoint for our full-year revenue guidance by $75 million while keeping our outlook ranges unchanged for operating profit, adjusted EBITDA, EPS, and free cash flow. Now let me walk you through the assumptions behind that guidance, beginning with revenue. To start, all 3 products in our innovative portfolio — AUSTEDO, AJOVY, and UZEDY — are delivering strong results. Following that robust first half, we're raising the combined guidance for these products by roughly $150 million at the midpoint, which points to a combined 2026 revenue outlook of approximately $3.7 billion, representing growth of approximately 17% over 2025. Conversely, for the full year we anticipate our Global Generics revenue will be flat to down low single digit in local currency versus 2025, once you exclude the impact of generic REVLIMID mid and the divestment Japan business. The main reasons are fewer high-value launches in '26, lower seasonal on OTC, and heightened competition in certain markets. Turning to the remaining pieces of our financial outlook: we still expect 2026 non-GAAP gross margin to land in the range of 54.5% to 55.5%. Beyond the MLX related expenses this year, operating expenses should come in at approximately 28% of revenue for the full year.

Eliyahu Kalif executive
#7

At this point we're at the top of the 27% to 28% range for total OpEx, which reflects a deliberate spend on our part to support both our growing innovative portfolio and our biosimilars. The outlook we've provided for operating income and EBITDA factors in this larger OpEx growth investment, along with a less expected in the second half. Let me now take you through some additional considerations regarding how our quarters will be phased over the rest of the year. Across the remainder of the year, we anticipate overall revenue will be higher. Regarding AUSTEDO, channel inventories remain higher than we'd like, and we anticipate that surplus stock will work itself out across the coming 2 quarters. Our expectation is also unchanged that AUSTEDO revenue for Q4 '26 will decline compared with the prior year, driven by the purchasing pattern and pricing environment shifts we foresee leading up to the January start of IRA implementation. Beyond that, we are preparing to launch our olanzapine LAI in Q4. Since early volume should consist largely of samples or vouchers while payer coverage gets built out, plan on seeing no revenue during Q4. Regarding our non-GAAP margin, we anticipated gains during the back half of the year, consistent with revenue trends plus larger cost reductions from transformation initiatives already underway, though gross margin should dip somewhat in Q4 compared with Q3 owing to expected revenue movements tied to AUSTEDO. We foresee operating margins rising quarter over quarter in Q4, propelled by savings on OpEx. Moving to the following slide about capital allocation: across recent years, we've achieved considerable headway in making our balance sheet stronger. That headway gives us the financial latitude to put money into our innovative portfolio and pipeline, to assess BD opportunities that add value, and to retain the option of giving capital back to shareholders via a buyback at the right time. Finally, a quick note on what we intend to do about moving to a direct ordinary share listing on the New York Stock Exchange. Our thinking is that this step opens Teva shares up to a wider group of investors, who will gain the ability to purchase ordinary shares straight away without friction, and there's also the possibility of being added to the major indexes. We expect to wrap this transition up in September, and we see it as one more sign of how committed we are to building shareholder value over the long term. Richard, over to you for your closing remarks.

Richard Francis executive
#8

Thanks, Eli. I want to stress again how exciting this is for Teva as we move into the acceleration phase of our pivot to growth strategy. This slide shows we have multiple opportunities to drive revenue in the near term, the medium term, and the longer term, and this innovative portfolio is really wide-ranging. I should also point out how many biosimilars we'll be bringing in as we start launching those into the market. as well as moving forward. So over the near term, our incremental growth is going to come from the next generation of innovation, but there's a lot more coming after that. And to wrap up, we're continuing on our growth journey. A few key points stand out. During a pivotal year for Teva, we accomplished precisely what we had committed to. Our pipeline is moving forward quickly, and our approach to allocating capital with discipline is, in our view, what distinguishes us. With that said, I'm eager to take some of your questions alongside the team here. Many thanks.

Chris Stevo executive
#9

So as Elliott gets ready with the questions, I’d like to remind all of you to please try asking 1 question along with 1 short follow-up. If you’d like to ask more after that, we’ll gladly put you back in the queue, but doing it this way lets as many people as possible have a chance to ask something. So Elliot, when you’re set, we can begin.

Jason Gerberry analyst
#10

Nice work this quarter. I wanted to ask a follow-up — AUSTEDO has clearly performed very well. I believe you said new patient starts account for 60% share. I'm trying to gauge how confident you are that heading into next year, AUSTEDO won't be put at a disadvantage on formularies as a drug with a lower WACC price, and that payers will keep in mind they shouldn't leverage the IRA negotiated price point to give the competitor drug an edge. So I'd just like your broad take on that. Then, as a quick second question from me, do you have any thoughts on the U.S. tariff update and how the supply chain is set up so that risk can potentially be managed?

Richard Francis executive
#11

Thanks, Jason. Could you say that last question again? I didn't catch it.

Jason Gerberry analyst
#12

Yeah. My apologies — what I meant to ask was whether you have any perspective on the tariffs Trump has proposed for the U.S., and on how the supply chain has been set up to reduce that exposure?

Richard Francis executive
#13

All right. Appreciate that question, Jason. First, it's good to see you acknowledge how strongly AUSTEDO has performed, at 40%. One thing I'd like to adjust, though: I believe your figure was 60% of new starts. That 60% figure I mentioned actually refers to 60% of new AUSTEDO starts being on AUSTEDO XR — just to clear that up. Even so, our TRx growth remains quite strong, and milligram growth is strong too, which shows how much AUSTEDO XR helps patients reach the optimal dose and stick with it and comply better. Now, on your question about payer dynamics for 2027: this is an area we've invested a great deal of time examining. A few scenarios could obviously unfold here. Still, it deserves emphasis that every Medicare plan has to cover negotiated products on its Part D formulary. That would include, clearly, AUSTEDO XR. Given that, and given the product profile along with substantial patient demand and the enthusiasm physicians have shown for AUSTEDO XR, I'd say our confidence holds that we can keep capturing a large number of patients as 2027 arrives. As for how revenue gets affected, that isn't really something we're addressing right now. We've made clear that guidance will come. When we issue guidance for the company, additional data will emerge as things progress. And clearly, later in the year we'll wind up having further conversations with certain payers. Even so, our confidence on this remains strong. I'd also like to restate what I put in my notes: we are very committed to peak sales above $3 billion, given the large untreated patient population and, plainly, the momentum behind the brand and how the team has executed. Turning now to your second question, about the administration's recent announcement regarding the Trump tariffs: this news has only just emerged, naturally, so we're processing it and working out what it might mean. I'd add, though, that we do operate a number of factories inside the United States. I believe we rank as 1 of the biggest generic manufacturers in the U.S. Still, we have some time to sort this 1 out and figure out what the administration is attempting to accomplish. And as you'd expect, given how much we contribute to the U.S. health care system, we've consistently stayed in close talks with the administration. So thank you for asking.

Umer Raffat analyst
#14

Before the Celiac data comes out, I'd like to take a moment on the IL-15 and dig into a few aspects. First, my understanding is that the final patient was enrolled on April 7, so by early June they ought to have completed the week 8 endpoint. So I'm simply attempting to grasp the data timing. My assumption had been that it might arrive as soon as today, possibly alongside earnings. I recognize that wasn't the expectation, but I just want to grasp the timing and where things stand regarding analysis of the data. Also, you previously disclosed something from a Phase Ib exploratory celiac study showing a separation against placebo. However, the biomarker represented on the Y-axis wasn't identified. Which biomarker was it? And last, could you remind us of the daily gluten background amount being used in the celiac study you have underway, or the celiac study you've already finished?

Richard Francis executive
#15

Thanks for the question. I sense you're nearly as demanding as I am about seeing results as quickly as possible. That said, I'll pass it to Eric for the answer.

Eric Hughes executive
#16

Thank you, Umer. I appreciate that question — it's quite precise and timely. Let me start with enrollment. The enrollment figures you're seeing on clinical drives — shifts in those numbers don't necessarily line up with the timing of our database lock. That's really the straightforward response. That's just how it works; nothing here is moving slowly or quickly. It simply is what it is. So that data will come in the second half of this year. Now, regarding the biomarker question from the first POC — that was an FSB free acid binding protein. I believe I have that correct, free acid binding protein. It's a biomarker, and it's fairly commonly used for measuring gut inflammation, and the separation we observed between placebo and active upon those gluten challenges — honestly, it was exciting for me to witness, because it clearly showed we're having an impact. One thing I always like to bring up: if you speculate or read too much into the data, not only did we protect that got with this biomarker by that readout, but it appears to actually improve on — from the baseline. So whether we're treating a smoldering celiac in those patients is something fun to speculate about. So it was this free acid binding protein in that study. Then your last question concerned the amount of gluten challenge we're administering in the biopsy study that will read out in the second half of this year. We're giving 3 grams every day for 6 weeks; that's a significant challenge in that study. I think that team considered there are various different ways you can do it, but that's a significant amount. I'm always impressed to see that we can enroll patients that are willing to do that. So hopefully, that answers all your questions.

Louise Chen analyst
#17

I'd like to inquire regarding the biosimilars chance you have. It appears you're discussing that subject more often. I'm just wondering whether you might provide a bit more detail about the reasons this growth prospect is turning into something more significant for you at present? Also, is there anything shifting within the U.S. market — any possible moves from regulators or payers on the horizon — that might unlock this market further?

Richard Francis executive
#18

Louise, I appreciate that question. Indeed, you're correct — we're thrilled. The biosimilars excite me. We've put in serious effort to build the portfolio and bring it to market. I believe there are a few factors behind my enthusiasm. One is simply how our U.S. team has performed in the market. For some context, we haven't consistently been first to launch. Yet what we've demonstrated — and what I pointed out today — is that 2 of our 5 products in the U.S. market hold the #1 spot. And I believe a third 1 is on the verge of taking #1. That demonstrates, in my view, our capability, which connects somewhat to the second part of your question: what has shifted in the U.S. market? Well, honestly, nothing is truly shifting. It's genuinely a tough, complicated, fragmented market. Why do I come across as somewhat upbeat about that? I'm not; yet what I do know is that due to our reach, our scale, and the scope of what we do, we can navigate what is a highly fragmented, complicated market. That, I think, explains why you're sensing my enthusiasm and seeing the performance we've achieved in the U.S. Should changes occur, I believe those would be beneficial too, since we'd gain from them; but we have an increasing number of products arriving in the U.S. Now in Europe, where biosimilars have really left us starved, we're beginning to launch them there. What we observe is that the earliest signals indicate when we launch them — as you'd anticipate, once again from Teva, a major player across all European markets — our capacity to perform strongly right away, early signs suggesting we can achieve that. So the reason I'm excited overall is that, as you combine these 15 biosims, another 14 in the pipeline, plus additional partnerships we're pursuing, I think this will become a major growth driver for our generics business overall; that's where my enthusiasm comes from, and I hope we'll have many more data points to showcase that. And perhaps to wrap up, we set a target of $800 million by 2027, as I mentioned today on the call; we're well on track to surpass that already; so thank you for the question, Louis.

Dennis Ding analyst
#19

I wanted to ask something about celiac. You've mentioned that 4 Phase Ib serves as the benchmark in CD, yet that figure was 0.127 adjusted for placebo, and the error bars were extremely wide. So really this breaks into two parts. First, what's the reason we shouldn't treat the CALYPSO data as the benchmark, which I believe sits somewhere around 0.4 to 0.5 million? Second, could you speak to how we should interpret your data — if you were to see, say, 0.15, 0.2, or 0.3, would that strike you as clinically meaningful? Or is there something else in what you've disclosed that you'd want to direct us toward?

Richard Francis executive
#20

Eric, over to you?

Eric Hughes executive
#21

Yes. Thanks, Richard. So Dennis, we're relying on the reference bars available to us. My apologies. Forte is the one that reported the figure of 0.127. As for the CALYPSO data, I'm not certain whether that's something we can readily access at this moment. So if we're able to obtain those data, it would be excellent to use them for comparison. What I think matters most is remembering that all of these are somewhat artificial gluten challenges — they differ from one study to another; we created a study that we believe will produce a solid result from a single dose. Keep in mind, we're administering one dose and examining a 6-week challenge with a fairly substantial gluten burden. The key point is observing that delta between placebo, which ought to shift the most. And with luck, the active will remain comparable. So the one that's documented the most, and in my view the most comparable, is the forte figure of 0.127 that you brought up, and that represents the delta between placebo and active. So I'm still essentially saying that's what we'll use as our benchmark when it comes to the results we can access. Regarding the CALYPSO data, I don't have familiarity with it. I'm unsure whether it was posted or can be obtained at present. So perhaps we can circle back with you to make that comparison. There are many different things we'll obtain — we'll gain knowledge from this study, not just the biopsy data, which is critically important for figuring out how we structure the Phase II and III studies, but also experiential or symptomatology data. So there's plenty ahead there, but I believe at this point we're going to stay with comparing against forte.

David Amsellem analyst
#22

Let me ask two things — first about 408, then about ecopypane. On 408, especially now that Forte has been bought, Eric, I'd like your perspective: mechanistically, how do you see 408 compared with drugs that target CD122 and work through IL-15 and IL-2? And do you believe those agents might or might not hold an edge over 408? That's a wide-ranging one. I suppose it spans several indications, including vitiligo and celiac, and possibly more. Second, regarding ecopitane, could you address how it would be positioned in the market? When you consider its D1 antagonism activity, do you see a chance it could be given before the antipsychotics approved today, which mostly act on D2? What's your thinking there, particularly given that those products are available generically?

Richard Francis executive
#23

All right. Eric, would you like to begin with NGL50?

Eric Hughes executive
#24

Yes. All right, thanks for asking that. So to start, I should probably talk about the competition and how we go about creating anti IL-15 compared with the way Forte does it. Neither of the 2 approaches is flawed. You can target the receptor, which is what Forte did, or you can target the leg, which is what we did with. There are a few things we think about strategically when designing molecules; we prefer to target the ligand. It's clean. You hit the free ligand and the cytokine in the system. When you target a receptor, you risk generating some off-target complications by doing that. From a strategic standpoint, our approach differs, though both paths have merit. There's another, less obvious advantage to hitting the ligand: you gain the ability to gauge target engagement. In our case, we quantify the unbound anti-IL-15 present in the system, which provides a reliable read on the level of activity at any given moment over time. What we've shown is that a single dose can hold free IL-15 suppressed for as long as 80 or 90 days. That gives you a genuinely data-driven basis for settling on your dose and schedule. It's the reason we're studying a dose administered every three months — a quarterly injection we're creating for subcutaneous delivery. Therefore, the main distinctions come down to strategy. Is one better than the other? That's unknown. What I can say is that I have strong faith in how we've modeled and simulated our path forward, which involves a straightforward subcutaneous injection administered once every three months. Those are, in my view, the most significant contrasts. Seeing this acquisition is wonderful — it demonstrates how much worth people assign to conditions such as vitiligo and celiac disease. I feel quite certain these will become indications that expand much like psoriasis did, much like atopic dermatitis did. As soon as effective therapies that are simple to administer become available, they'll be adopted and the market will grow. That covers your first question. So when you look at where ecopipane fits in the treatment journey for Tourette disease, patients typically start with behavioral therapies. If those aren't enough, they move on to off-label options — things like glyphenesene and other unapproved drugs. Those can help somewhat; the benefit isn't huge, though patients do handle them reasonably well. From there, they progress to antipsychotics. Those do work, but people don't tolerate them very well, and that's especially true for kids. That's where our differentiation comes in: we're offering a completely new mode of action — a D1 antagonist — and it's far better tolerated. Based on what we saw, tolerability was very good in both the Phase III and Phase II studies. Our expectation is that initially these may not be used as initial treatments, yet as time passes and the safety profile along with the effectiveness becomes apparent, they would likely move earlier in the sequence. That's my view on how adoption would unfold and the benefit we bring with it.

Richard Francis executive
#25

Absolutely, and let me jump in here, Eric, to build on that point. The data really does support what I'm saying. Like I mentioned, 100,000 pediatric patients are dealing with Tourette syndrome, and just 50% of them get treatment — which really raises the question of why that is. I believe it comes down to this: no product out there delivers both efficacy and safety. That idea gets even more support when you look at the fact that merely 20% to 30% stay on their therapy. And again, one theory behind that is that I'm not certain parents are comfortable having their kids on antipsychotics for the long haul, or that some of the other medications simply aren't effective enough. So no matter how you frame it, there's a significant unmet medical need for something that works well, is safe, and is well tolerated. Combine that with what we bring in the U.S. through our know-how with AUSTEDO, UZEDY, and AJOVY — knowing how to serve specific patient populations — plus our background working with psychiatrists and neurologists. That's exactly why we're so enthusiastic about the opportunity to support these patients, these children living with such a difficult condition.

Ashwani Verma analyst
#26

Excellent. Could you discuss the TL1A new indication, specifically regarding that fibronostics indication you brought up — what kind of addressable market does that represent when it comes to patients in the U.S. and Europe? And regarding HS, how would the development path and trial design be structured? Would it follow the usual Phase II and Phase III approach, centering on high 50 as the primary end point?

Richard Francis executive
#27

Appreciate the question. I'll pass that one over to Eric — you're having quite a busy day today.

Eric Hughes executive
#28

Thanks, I’m glad you asked. Two indications really get me excited, and I want to explain how we and our partner Sanofi assess indications: first comes a strong scientific rationale, next is the market opportunity, then the probability of regulatory success, and of course, speed. Those are the four criteria we use when choosing; so why HS and fibrosinotic cronies, then. A substantial body of strong science backs the notion that TL1A is upregulated in these disease areas, that Th1 and Th17 cells are involved, and that a drug such as do we keep is needed to affect multiple separate pathways. Then you add in the possibility of a direct effect on fibrosis. When you put all those pieces together, it points to HS being a pretty compelling target. On top of that, roughly one in seven IBD patients—15%—also deals with HS. So there's ample scientific rationale supporting this as a viable therapy. HS represents yet another expanding market—you can see that reflected in what competitors are doing. It's an area with significant unmet need, it will keep growing, so the commercial opportunity clearly exists. I'd say our odds of success look favorable, and we can move on this quite fast. Typically the primary endpoints land at about 16 weeks—that's probably the route we'll take. So where we stand now in development, the plan is to run a standard Phase IIb trial, and from there we'd move into a Phase III program — that's the basis for the timelines we're considering in HS. Moving on to fibrostynatic Crohn disease: this is another one that, in my view, is a really strong idea. It represents an area with substantial unmet medical need. For the indication of fibrostononic Crohn disease, no therapies have been approved. And it's genuinely one of the primary things driving complications in Crohn's disease, where obstruction can occur. Hospitalizations happen. You see higher costs, and more symptoms. If a medication could do more than just halt inflammation—if it could actually address those serious, obstructive fibrotic lesions that show up in Crohn's disease patients—that would set it apart in a big way for any drug entering the IBD space. Ideally, one day we won't simply be discussing how to switch off inflammation in Crohn's; we'll be discussing how to alter the disease's structure and its major complications. When I look at what's possible here, it's about more than just a scientific breakthrough on fibrosis—it means securing a stronger label, wider possibilities for patients, and a bigger commercial chance for the company. That's what guides the approach to the 2 indications, and I believe they're exactly right.

Richard Francis executive
#29

I think we have time for 1 more question. Is that right?

Glen Santangelo analyst
#30

Yeah, Glen Santangelo here. I believe the name was incorrect. Anyway, Elliot, I have just 2 brief questions for you, if that's okay. Basically, during the prior quarter, I believe you mentioned the inventory problems with Osteo. And my understanding was that those stock levels were supposed to decline somewhat in this quarter, yet it appears that didn't happen. And I believe you indicated those inventory amounts are still somewhat high. So in what way should we consider that for 3Q and 4Q, given the guidance figures you provided? Then second, I wanted to inquire about EBITDA. Given how strong the innovative brands were this quarter and how impressive your revenues and gross margin were, you kept the EBITDA guidance the same. And I was just wondering whether anything changed regarding your expense outlook that might be worth highlighting, since that EBITDA guidance was maintained?

Richard Francis executive
#31

Glenn, this is Richard, thank you for asking. I'll begin with the stat, then pass it to Eli regarding the EBITDA question. So concerning this inventory, you're correct, that buildup happened in Q4 2025. And we anticipated a drawdown; some of that drawdown did happen during the first half of the year, though it wasn't entirely finished; therefore we need the remaining portion to decrease in the second half of the year and Q4. Then, to repeat what I believe we've also stated, how will Q4 levels ultimately turn out, given that the IRA price effectuation arrives in Q1 2026. And I think that's something we're also taking into account as we consider guidance for AUSTEDO. Then I return to the fundamentals: is the TRx solid? Yes. Is the milligram growth solid? Yes. Is our breadth and depth of prescribers solid? Yes. So I think that provides us, clearly, confidence regarding where the product is going, which is why we feel confident about $3 billion plus in peak sales; but those are simply the dynamics as we navigate this inventory, both the early portion from Q4 '25 and then figuring out how that will unfold in Q4 of this year; and regarding EBITDA, I'll pass that 1 to Eli.

Eliyahu Kalif executive
#32

Appreciate the question. Yeah. So, as I said during our prepared remarks, and as you could see from the slide, the 3 main products — AUSTEDO, AJOVY and UZEDY — are now at the midpoint moving toward $150 million. But when you look at the very top of our top line, net-net-net, the midpoint you see is EUR 75 million, and that ties to a kind of offset we're seeing because of some softness in generics, which I already mentioned. Overall, it's really important to keep in mind that this is a very strong performance, especially when you consider the backdrop of a tough prior year comp, with $1.1 billion of revenue and $700 million of equivalent EBITDA removed from REVLIMID. Now, if you move to the EBITDA range we gave, we should recognize that I said we'd land at the higher end of the OpEx range, around 28%, and that's tied to some ongoing investment we're making to ensure our innovative portfolio in biosimilars performs. And we also had a little bit less, I'd say, plus some other in-line costs that showed up in our first half and will show up in the second half. You saw the announcement on OCREVUS, and a small item here, a small item there. So it amounts to maybe a very small 20, 30 basis points on the total, if you look at annual revenue. But all of this reflects dynamics tied to investment in supporting our innovative and biosimilars portfolio.

Richard Francis executive
#33

Appreciate that, Glen. And actually, I've just noticed — we are going to keep taking a few more questions here. So that's 2 additional questions. On to the next one.

Matt Dellatorre analyst
#34

Great. Perhaps returning to TL1A — it appears you folks are leaning somewhat heavily into those diseases where fibrosis is a major factor. So I suppose, how far might you be able to push in that direction when it comes to further fibrotic indications? Will you sort of watch how these things turn out and then proceed from there? And then Eric, you mentioned this only in passing, but I suppose, how should we frame it in the sense of whether this would mostly serve as a differentiator on your CD label? Or might it be a separate indication with a different label? And then maybe just quickly addressing the commercial angle. I'm aware you folks are getting ready for 2 big launches within the next 12 months involving olanzapine and EcoPPAM. Maybe just take us through launch preparations up to now? And what are you folks just most concentrated on from an execution standpoint for both of those launches?

Richard Francis executive
#35

I'll have Eric begin with TL1A 22. Over to you, Eric.

Eric Hughes executive
#36

Yeah. So, Matt, I appreciate the questions. And to begin with TL1A, why we picked HS and fibers Crohn's disease — the main reason is that these are inflammatory conditions that also involve a significant fibrotic element. So these are excellent ways to enter the field and demonstrate whether we're actually having an effect. We still need to prove that TL1A delivers that antifibrotic impact; but these are terrific paths to get in and learn. Once we've demonstrated that, sure, perhaps down the road we could move into purely antifibrotic or fibrotic conditions like IPF or similar. But at this point, we have to establish the principle; and these are excellent indications because — as we learn those things, we'll demonstrate tremendous value in indications with a high unmet medical need. Now, turning to your question about fibrostenotic Crohn's disease, and what our plans are for those going forward? My belief and my hope is to have that as a labeled indication one day if we generate strong results. So that's what those are intended for. So that genuinely could set us apart within the inflammatory bowel disease space. So that's the goal. And then regarding the launch of ecopipane and our preparations, perhaps, Richard, would you like to address that?

Richard Francis executive
#37

Right. No — the way you put it, there were two significant launches that have us quite thrilled. About olanzapine, I'd say it deserves mention that this launch has been in our planning for quite a while, considering the best way to go after it, yet that groundwork has genuinely been top-notch, not merely due to how the team thinks, since we are in the field daily, grasping the doctors, the individuals receiving care, the insurers, the complexities of this particular market; therefore the team has invested an enormous amount of work getting ready, which explains why we feel so hopeful and eager about our capacity to genuinely assist those individuals who require a prolonged-acting treatment for these serious schizophrenia cases; so I'd say quite assured and eager to watch that launch happen. On icopipane, if the FDA sticks to its schedule, we'd probably see it land in the back half of Q2 next year. Again, that asset's already been transacted—it's ours now. We'd been putting in work and thought on this for a while before we got near the deal, and we believe it fits our wheelhouse. Rare disease, patients who aren't getting enough treatment, figuring out how to motivate them to pursue therapy, figuring out how to teach physicians about something new. That probably sounds a lot like what we've been saying about AUSTEDO, and that's because it is. So that expertise and knowledge is going to give us a lot of leverage. Clearly, assembling the necessary resources and bringing the right individuals on board is something we excel at. There's a substantial unmet need here, so we're quite thrilled about it, and I believe the schedule actually lines up well since these are more than twelve months apart. We need to grow accustomed to this, because, as I mentioned earlier, a new product will be introduced annually. So this is a capability we've been developing; we're excited about it; we aren't fully committed across the board. We're moving toward it with energy. And therefore, I believe you'll witness a fantastic launch of. Naturally, though, we'll share further updates as we approach that point. So thank you for your questions, Matt. I believe the following one will be our final inquiry. Yes, this is the last question we'll take. So, who's up?

Chris Schott analyst
#38

This is Catarina sitting in for Chris. Just 2 really fast ones. First, regarding the AJOVY outlook for the year, it's shaping up well. What portion of that is driven by volume as opposed to price? And is there any additional color you could share about the trends you're observing for that product? Then, very briefly on Europe, it came in slightly below what was anticipated. Again, is there anything worth flagging there? And what should we expect from Europe's results in the back half?

Richard Francis executive
#39

Appreciate the question; regarding AJOVY, we're quite happy with how it's performing. Like I mentioned, this spans every market; we're seeing solid growth internationally, solid growth in Europe, and solid growth in the U.S. As I pointed out during my remarks, within the U.S., there's a bit of favorability around contracting and what we've accomplished on gross to net, plus we've gained market share in the U.S. We've gained market share in Europe and international markets as well. And it's worth noting that in every one of our regions, we're expanding faster than the market. So I believe that provides us a solid underlying trajectory across every region, along with some strong execution. I frequently remind folks that when we began this pivot to growth journey, AJOVY had essentially been neglected; and today we're discussing a $1 billion asset. I attribute that to the teams across all 3 regions being capable of pulling that off; now, you also raised a question about Europe and the weakness there. And I believe this ties back to something else I mentioned, which is that we don't have as many high-value launches as we did last year. We also experienced a very mild cough and cold season, and we hold a particularly significant portfolio in cough and cold, so that had an impact on us. On the brighter side, we're launching additional biosimilars. They've only just begun, so we haven't truly observed the traction from those yet; but we have increasingly more coming into Europe, which is a highly attractive biosimilar market and is 1 that I've been disappointed we haven't been in. But we've put a lot of effort into this portfolio, and we're bringing increasingly more biosimilars to market nearly year-on-year. As I mentioned, we have 14 additional ones to launch, and we're going to steadily add more to that portfolio, and eventually we'll have a portfolio in the mid-30s, approaching 40%; that's our ambition. So hopefully, that addresses your questions, Katherine, but thanks for asking them. And then do we have 1 more, a bit confused? No, we don't have any more; so thank you, everyone, for your time and attention today. Thanks for the questions, and thank you, as always, for the interest in Teva.

Operator operator
#40

That wraps up this session, everyone. We appreciate all of you joining us. At this point, please go ahead and hang up.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Teva Pharmaceutical Industries Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Teva Pharmaceutical Industries Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.